

References

- *Alnemri E.S., Litwack G. (1992):* Activation of internucleosomal DNA cleavage in human CEM lymphocytes by glucocorticoid and novobiocin: Evidence for non – Ca^{+2} requiring mechanism (S). J. Biol Chem; 265: 17323.
- *Aminas A.G., (1991):* Malignant disease of the uterus. In : Clinical Gynecology Varma Tr (ed). Edward Arnold, London: 480-507.
- *Anderson B., Marchant D.J., and Mun Zenrider JE (1987):* Routine noninvasive hystero-graphy in the evaluation and treatment of endometrial carcinoma, Gynecol Oncol; 4: 354.
- *Arends, M.J. and Wyllie, A.H. (1991):* Apoptosis: mechanisms and roles in pathology. Int. Rev. Exp. Pathol., 32: 223- 224.
- *Arends, M.J. and Wyllie, A.H. (1991):* Apoptosis: mechanisms and roles in pathology. Int. Rev. Exp. Pathol., 32: 223- 224.
- *Atlante G., Pozzi M., Vincenzoni C., and Vocaturi. G, (1990):* Four case reports presenting new acquisitions the Association between breast and endometrial carcinoma , Gynecol Oncol; 378-380.
- *Baak J.P.A., Kuik. D.J., Bezemer P.D (1994):* The additional prognostic value of morphometric nuclear arrangement and DNA-ploidy to other morphometric and stereological features in endometrial hyperplasia. International Journal of Gynecological cancer; 4: 289-297.
- *Bakhashi, A., Jensen,J.P. and Goldman,P. (1985):* Cloning the chromosomal breakpoint of t(14,18) human lymphomas: clustering

- around JH on chromosome 14 and near a transcriptional unit on 18. Cell, 41: 899- 906.
- **Bakhshi, A., Jensen, J.P. Goldman, P. and Korsmeyer, S.J. (1985):** Cloning the chromosomal breakpoint of t (14;18) human lymphomas: clustering around HJ on chromosome 14 and near a transcribtionaal unit on 18. Cell; 41: 899-906.
 - **Bardeesy N., Beck with J.B., and Pelletier J. (1995):** Clonal expansion and attenuated apoptosis in Wilm's tumours are associated with p53 gene mutations. Cancer; 55:215-219.
 - **Beauchamp R.D., Barnard J.D, Mccutchen C.M, coffey R.J. (1989):** Localization of transforming growth factor alpha and its and receptor in gastric mucosal cell. J. Clin. Invest; 84:1017.
 - **Beral. V; (1985):** Epidemiology and etiology of cancer of the female genital tract. In: Clinical Gynecological Oncology . shepherd JH and managhan JM (eds), Blackwell, Oxford. 1-14.
 - **Berman M, and Berek J.S. (1990):** Uterine carcinoma. In: cancer treatment third Edition. W.B. Saunders Company 338-35.
 - **Bernstein L.R. Liotta L.A. (1994):** Molecular mediators of interactions with extracellualr matrix components in metastasis and angiogenesis. Curr Opin. Oncol; 6: 106.
 - **Beutler, H.K., Dokerty, M.B. and Randall, L.M. (1963):** Precancerous lesions of the endometrium. Am. J. Obstet. Gynecol., 86: 433.

- **Beutler, H.K., Dokerty, M.B. and Randall, L.M. (1963):** Precancerous lesions of the endometrium. *Am. J. Obstet. Gynecol.*, 86: 433.
- **Bhargava V., Kell D.L., Van de Rijn M., et al., (1994):** Bcl₂ immunoreactivity *Am .J. Pathol*; 145: 535-540.
- **Bissonette R.P., Echeverri F., Mahboubi A., et al ., (1992):** Apoptotic cell death induced by c- myc is inhibited by bcl-2. *Nature*; 359:552-554.
- **Bloomer W.D, and Howes A.E. (1991):** Carcinoma of the endometrium, In: comprehensive text book of Oncology volume two, second edition Moosa Ar and Schimpff S.C. (eds) Williams & Wilkins. 1029-1035.
- **Bokhman, J. (1983):** Two pathogenetic types of endometrial carcinoma. *Gynecol. Oncol.*, 15: 10- 17.
- **Boyd, J.A. and Kaufman, D.G. (1990):** Expression of transforming growth factor in human endometrial carcinoma cell lines: Inverse correlation with effects on growth rate and morphology. *Cancer Res.*, 50: 3394.
- **Boyd, J.M., Gallo, G.J. Elangovan, B. and Malstorms, s. (1995):** Bik-1, a noval death inducing protein shares a distinct sequence motify with bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. *Oncogene*; 11: 1921-8.
- **Bradford, M.M. (1976):** A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. *Anal Bioch.*, 72: 248- 251.

- **Brinton L.A; Berman M; Mortel R., Twiggs L.B.; Barrett R.J., Wilbanks GD, Lannom L., and Hoover R.N. (1992):** Reproductive, Menstrual and medical risk factors for endometrial cancer: Results from a case control study.. Am.J. Obst. Gynecol; 167: 1317-1325.
- **Bur, M.E., Perlman, C., Edelmann, L. et al (1992):** p53 expression in neoplasms of the uterine corpus. Am. J. Clin. Pathol., 140: 145- 153.
- **Burke T.W., Eifel P.J, and Muggia F.M. (1997) :** Cancer of the uterine Body. In: Cancer Principles & Practice of Oncology 5th edition Philadelphia, Lippincott Raven, P. 1478.
- **Bursch, W., Paffe, S. and Putz, B. (1990):** Determination of the length of the histological stages of apoptosis in normal liver and altered foci of rats. Carcinogenesis, 11: 847- 853.
- **Campisi J, Dimri G.P, Hara E. (1996):** Control of replicative senescence. In Hand book of the biology of Aging, 4th ed. Edited by Eschneider, J. Row. New York: Academic.
- **Castronovo. V, Kusaka. M, Gielen J, Sobel M. (1994):** Home box genes. Potential candidates for transcriptional control of the transformed and invasive phenotype Biochem Pharmac; 47: 137-143.
- **Chambers J.T, and Chambers S.K (1992):** Endometrial sampling when? Where? Why? With what? Clinical Obstetrics and Gynecology 35(1).
- **Chan W.K., Mole M.M., Levison D.A., et al (1995):** Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarcinoma. J. Pathol; 177: 241-246.

- **Chan, W.K., Mole, M.M., Levison, D.A., Ball, R.Y., Lu, Q.L., Patel, K. and Hanby, A.M. (1994):** Nuclear and cytoplasmic *bcl-2* expression in endometrial hyperplasia and adenocarcinoma. *J. Pathol.*, 177: 241-246.
- **Chan, W.K., Poulson, R. and Lu, Q.L. (1992):** *bcl-2* expression in invasive mammary carcinoma: correlation with apoptosis, tumor grade and hormone receptor status. *J. Pathol.*,
- **Chen-Levy, Z. Nourse, J. and Clearly, M.L. (1989):** The Bcl-2 candidate proto-oncogene product is a 24 kilodalton integral membrane protein expressed in lymphoid cell lines and lymphomas carrying the (14:18) translocation. *Mol. Cell Biol.* ; 9: 701-710.
- **Chhieng, D.C., Ross, J.S. and Ambros, R.A. (1996):** *bcl-2* expression and the development of endometrial carcinoma. *Mod. Pathol.*, 9: 402- 406.
- **Clark- Pearson DL, and Dawood M.Y., (1989):** Endometrial cancer and uterine sarcoma. In: *Green's Gynecology: Essentials of clinical practice*. Fourth edition. Little Brown and Company. 521-530.
- **Clearly, M.L. and Sklar, J. (1985):** Nucleotide sequence of a t(14,18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. *Proc. Natl. Acad. Sci. USA*, 82: 7439- 7443..
- **Cleary, M.L., Smith, S.D. and Sklar, J. (1986):** Cloning and structural analysis of cDNAs for *bcl-2* and a hybrid *bcl-2*/immunoglobulin transcript from the t(14,18) translocation. *Cell*, 47: 19.

-
- **Clemens A.S, and Scott W. L. (1999):** Apoptosis and therapy. *J. Pathol*; 187: 127-137.
 - **Cohen C.J. and Thomas G.M. (1997):** Endometrial carcinoma. In: *Cancer Medicine*, fourth edition, Holland Jf, Morton Dl, Kufe D.W and Welchselbaum Williams & Wilkins, Maryland, P.2263.
 - **Collur, N. F., Manked,I. And Trope, A. (1992):** Interleukin-3 protect murine bone marrow cells from apoptosis induced by DNA damaging agents. *J. Exp. Med.*, 176: 1013- 1021.
 - **Cooper, G. (1997):** Cells signaling. In: *The cell . A molecular approach*. Edited by G. Cooper-2nd ed. ASM press, Washington, D.C., Chap. 13, p.521-540.
 - **Cotter, T.G., Glynn, J.M., Echeverri, F. and Green, D.R. (1992):** The induction of apoptosis by chemotherapeutic agents occurs in all phases of the cell cycle. *Anticancer Res.*, 12: 773- 780.
 - **Dane, D.P. (1993):** A death in the life of p53. *Nature*, 362: 786-787.
 - **David, C. chhieng, M.B., Jeffrey, S., Ross, M.D. , and Ambros, M.D. (1996):** Bcl-2 expression and the development of endometrail carcinoma *Mod. Pathol.*,9; (4): 402 406.
 - **De-Cecco L., Leone M., Gerblado . D, Venturini P.L, Rissone R. and Leone M, (1991):** Steroid therapy and the endometrium: biological and clinici implications. *Ann- N-Y-Acad- Sci*, vol 622, P. 296-301.
 - **Deligdisch,L. and Cohen, C.J. (1985):** Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. *Cancer*, 56: 1452- 1455.
-

- *Deporatore, V. and Golstein, P. (1997):* Fas and other cell death signaling pathways. *Semin. Immunol.*, 9 (2) : 93-107).
- *Deschamps J., Meijlink F., (1992):* Mammalian homeobox genes in normal development and neoplasia. *Crit Rev Oncogenesis*; 3: 117.
- *Devita, V. T., Hellmons, S. and Robsenberg, S., (1993):* In cancer Principles and Practice of Oncology, Devita, V.T (Ed) 4th edn., Lippincott Co., Philadelphia, P. 163.
- *Dexter T.M., Raff M.C., Wyllie A.H.eds (1995):* The role of apoptosis in development tissue homeostasis and malignancy R Soc. London Ser B; 345.
- *Dibold, J., Baretton, G., Felchner, M., et al (1996):* bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. *Am. J. Clin. Pathol.*, 105: 341- 349.
- *Disaia, P.J, and Creasman, W.T. (eds) (1993):* Endometrial hyperplasia and estrogen therapy. In: *Clinical Gynecologic Oncology*. Mosby, St. Louis, Toronto, 4th edn. P.122.
- *Dive C., and Hickman J.A. (1991):* Drug target interactions: only the first step in the commitment to a programmed cell death *Br. J. Cancer*; 64: 192-196.
- *Donehower, L.A., Harver, M., Slagle, B.I. McArthur, M.I. et al (1992):* Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. *Nature*, 356: 215- 221.

- ***Edlund, T. and Jessel, T.M. (1999):*** Progression from extrinsic to intrinsic signaling in cell fate specification: a view from the nervous system. *Cell*; 96(2): 211-24.
- ***Eissa, S. and Seada L.S. (1998):*** Quantitation of *bcl-2* protein in bladder cancer tissue by enzyme immunoassay: comparison with western blot and immunohistochemistry. *Clin Chem.*, 44: 1423- 1429.
- ***Fanidi A., Harrington E.A., Evan G.I. (1992):*** Cooperative interaction between *c-myc* and *bcl-2* oncogenes. *Nature*; 359:554-556.
- ***Ferenczy, A., Gelfand, M.M. and Tzipris, F.(1983):*** The cytodynamics of endometrial hyperplasia and carcinoma. *Ann. Pathol.*, 3: 189- 202.
- ***Finke J., Lange W., Mertelsmann R., et al (1994):*** Bcl-2 induction is part of the strategy of Epstein- Barr virus. *Leuk lymphoma*; 12: 413- 419.
- ***Finkler N.J., and Friedman A.H. (1990):*** The uterine corpus. In: Kistner's Gynecology Principles and Practice, fifth edition, Year Book medical publishers, Inc. Chicago 188-224.
- ***Fishel R., Lescoe M.H. Rao M.R.S. et al., (1994):*** The human mutator gene homology MSH and its association with hereditary nonpolyposis colon cancer. *Cell*; 77: 167
- ***Fleming, M.V., Guinee, D.G., Chu, W.S., Freedman, A.N., Bennett, W.P. and Travis, W.D. (1998):*** *bcl-2* immunohistochemistry in a surgical series of non-small cell lung cancer patients. *Hum. Pathol.*, 29: 60- 64.

- **Foley k., and Lee R.B., (1990):** Surgical complications of obese patients with endometrial carcinoma. *Gynecol Oncol*; 39: 171-174.
- **Fox. H., and Buckley C.H, (1991):** Malignant Neoplasm of the female Genital tract . In: *Pathologie for Gynecologists*, second edition. Edward Arnold. London 125-166.
- **Gannon, J.V., Greaves, R. and Lane, D.P. (1990):** Activating mutations in p53 produces a common conformational effect, a monoclonal antibody for the mutant form. *EMBOJ.*, 9: 1595- 1602.
- **Giatromanolaki, A., Sivridis, E., Koukourakis, M.I., Harris, A.L. and Gatter, K.C. (1998):** bcl-2 and p53 expression in stage I endometrial carcinoma. *Anticancer Res.*, 18: 3689-3693.
- **Gima, T., Kato, H., Honda, T., et al (1994):** DCC gene alteration in human endometrial carcinomas. *Int. J. Cancer*, 57: 480.
- **Ginnakis, C., Forbes, I.J. and Zalewski, P.D. (1991):** $\text{Ca}^{2+}/\text{Mg}^{2+}$ -dependent nuclease: tissue distribution and inhibition by Zn^{2+} . *Biochem. Biophys. Res. Commun.*, 181: 915- 920.
- **Glassburn J.R, (1981):** Carcinoma of the endometrium. *Cancer*; 48:575.
- **Gold,L.I., Saxena, B., Mittal, K.R. et al (1994):** Increased expression of transforming growth factor B isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: Evidence of paracrine and autocrine action. *Cancer Res.*, 54: 2347.
- **Gompel J.C., Sabourin C.J., Martin A. et al., (1994):** Bcl-2 expression in normal endometrium during the menstrual cycle. *Am J pathol*; 144: 1195-1202.

- **Guyton, A.G. (1991):** Cell production. In : Text book of medical physiology. 8th edn, W.B. Saunders. Company. London, Chap. 7, P.31.
- **Halder S., Negrini M., Monne M., et al (1994):** Down regulation of bcl-2 by P53 in Breast cancer cells. Cancer Res; 54: 2095-2097.
- **Henderson, M.D., Karen, A. and Brown , M.S. (1996):** Bcl-2 is down regulated in a typical endometrial hyperplasia and adenocarcinoma Mod. Pathol., 9; (4): 430- 438.
- **Hendrickson M.R., and Kempson R.L. (1980):** Surgical pathology of the uterine Corpus. W. B. saunders. Philadelphia 589.
- **Henzl, M.R., Smith, R.E. and Boost,G. (1972):** Lysosomal concept of endometrial bleeding in humans. J. Clin. Endocrinol. Metab., 34: 860- 875.
- **Hickman J.a., Potten C. S., Merritt A.J., and Fisher T.C. (1995):** Apoptosis and cancer chemotherapy, philos trans RSOC London Sr B; 345: 83-89.
- **Hockenberry, D., Nunez, G., Milliman, C., Schreiber, R.D. and Korsmeyer, S.J. (1990):** bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348: 334.
- **Hockenberry, D.M., Zutter, M., Hickey, W., Nahm, M. and Korsmeyer, S.J. (1991):** bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. USA., 88: 6961.
- **Hockenbery, D.M. (1995):** bcl-2, a novel regulator of cell death. BioEssays, 17: 631 – 638.

- **Hockenbery, D.M., Zutter, M. and Hickey, W. (1997):** Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. *Proc. Natl. Acad. Sci. USA*; 88: 6961-6965.
- **Hopwood, D. and Levison, D.A. (1976):** Atrophy and apoptosis in the cyclical human endometrium. *J. Pathol.*, 119: 159- 166.
- **Hoskins W.J, Perez C.A, and Young R.C. (1997):** In Principles and Practice of Gynecologic Oncology, 2nd edition, Lippincott-Raven Publishers, Philadelphia.
- **Howard J, Finger T. and Arthur B (1997):** Cell proliferation and differentiation. In: *Cancer medicine*, 4th ed. Edited by Williams and Wilkins. New York: P.3-18.
- **Hricak H, (1991):** Role of imaging in the evaluation of pelvic cancer. In: *Important advances in oncology* J.B. Lippincott Company 103-132
- **Hwang. I. (1999):** Defects in apoptosis. In: *Molecular Biology Cancer Medicine*. Edited by R.Kurzork and M- Talpaza, 2nd ed. Martin Dunitz Ltd, london; chap. 6, P.P. 134-146.
- **Ioffe, O.B., Papadimitriou, J.C. and Drachenberg, C.B. (1998):** Correlation of proliferation indices, apoptosis and related oncogene expression (*bcl-2* and *c-erbB-2*) and p53 in proliferative, hyperplastic and malignant endometrium. *Hum. Pathol.*, 29: 1150- 1159.
- **Irwin J.C., Utain W.H., Eckert R.L. (1991):** Sex steroids and growth factors differentially regulate the growth and differentiation of cultured human endometrial stromal cells. *Endocrinology*; 129: 2385-2392.

-
- **Ito, K., Watanabe, K., Nasim, S., Sato, S., Yajima, A., Silverberg, S.G. and Gaarrett, C.T. (1994):** Prognostic significance of p53 overexpression in endometrial cancer. *Cancer Res.*, 54: 4667-4670.
 - **Kaku.T., Tsukamoto N., Tsuruchi N., Sugiharak and Kamura T. (1992):** Endometrial metaplasia Associated with endometrial carcinoma. *Obest. Gynecol*; 80(5): 812-816.
 - **Kamesaki S., Kamesaki H., Jorgenesen T.J., Tanizawa A., Pommier Y., Cossman J. (1993):** Bcl-2 protein inhibits otoposide- induced apoptosis through its effect on events subsequent to topoisoemerase II-induced DNA strand breaks and their repair. *Cancer Res*; 53: 4251-4256.
 - **Kaprianou, N., English, H.F., Davidson, N.E. and Isaacs, J.T. (1991):** Programmed cell death regression of the MCF-7 human breast cancer following estrogen ablation. *Cancer Res.*, 51: 162- 166.
 - **Kelsey, J.L. (1982):** A case control study of cancer of the endometrium. *Am. J. Epidemiol.*, 116: 333.
 - **Kerr J.F., Winter ford C.M., Harmon b.V. (1994):** Apoptosis its significance in cancer and cancer therapy. *Cancer*; 73: 2013-2026.
 - **Kerr, J.F.R., Wyllie, A.H., Currie, et al (1972):** Apoptosis: A basic biological phenomenon with wide-ranging implications in tissu kinetics. *Br. J. Cancer*, 26: 239- 257.
 - **Kim N.W, Platyszek M, Prowse K. R, Shay. J.W. (1994):** Specific association of human telomerase activity with immortal cells and cancer. *Science*; 266: 2011-2015.
-

- **Kistner, R.W, (ed.) (1990):** Endometrial hyperplasia. In: Gynecology. Principles and Practice. R.W. Kistner (ed.) 5th ed. Year book publishers London. P. 228.
- **Kobayashi T., Ruan S., Clodi K., et al., (1996):** Over expression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemo therapeutic agents; *Oncogene*; 16: 1587-1591.
- **Kojima H, Endo K., moriyana H., et al., (1998):** Abrogation of mitochondrail cytochrome released and caspase- 3 activation in acquired multidrug resistance. *J. Biol Chem*; 273: 16647-16650.
- **Korsmeyer, S.J. (1992):** Bcl-2 initiates a new category of oncogenes: Regulators of cell death. *Blood*; 80:879-886.
- **Korsmeyer, S.J., Shutter, J.R., Veis, D.J. and Oltvai, Z.N. (1993):** *bcl-2/Bax*: a rheostat that regulates an antioxidant pathway and cell death. *Semin. Cancer Biol.*, 4: 327.
- **Kurman R.J, Kaminski F, Norris H.J. (1985):** The behaviour of endometrial hyperplasia: a long-term study of “untreated” hyperplasia in 170 patient. *Cancer*; 56:403-12.
- **Kurman, R.J. Zaino, R.J. and Norris, H.J. (1994):** Endometrial Carcinoma. In *Blaustein’s Pathology of the Female Genital Tract*. 4th edn. Edited by Kurman, R.J., New York, Spriner-Verlag, p 412.
- **Lane, D.P. (1993):** A death in the life of p53. *Nature*, 362: 786-787.
- **Lawrence W.D, and Gorden P.P. (1990):** Pathology of the genital tract in the postreproductive women. In: *Postreproductive Gynecology*. Churcill livingstone, New York. P. 23-84.

- *Leburn, D.P., warnke, R.A., Clearly, M.L. (1998):* Expression of bcl-2 in fetal tissue suggests a role in morphogenesis. Am.J. Pathol. 142:743-753.
- *Leek R.D., Kaklamanis L., pezzella F., et al (1994):* Bcl-2 in normal breast and carcinoma associated with oestrogen receptor-positive, growth factor, receptor-negative tumours and in situ cancer. Br J Cancer; 69:135-139.
- *Lehninger, A.L.; Nelson, D. and Cox, M. (1993):* Integration and hormonal regulation of mamalian metabolism. In: Principles of Biochemistry. Edited by A.L Lehninger, D. Nelson, and M. COX. 2nd ed Worth publishers, New York, chap. 22,P. 759-783.
- *Levi, Franceschis., Negri: E., et al., (1993):* Dietary factors and the risk of endometrial carcinoma Gancer; 71:3575.
- *Levine, A.J., Perry, M.E., Chang, A., et al (1994):* The 1993 Walter Hubert Lecture: The role of the p53 tumor-supressor gene in tumorigenesis. Br. J. Cancer, 69: 409- 416.
- *Lewin, B. (1990):* Driving the cell cycle; M-phase Kinase, its patterns and substrates. Cell; 61:743-748.
- *Lindahl B., willen. R, (1994):* spontaneous endometrial hyperplasia. A Anticancer Research; 14:2831-2834.
- *Lu Q.I., christopher S., and Elnasir L. (1996):* Bcl-2 role in epithelial differentiation and onco genesis. Hum. Pathol; 27:102-110.

- *Lu Q.I., Poulson R., Wong I., et al., (1993):* Bcl-2 expression in adult and embryonic non-hematopoietic tissues. J. Pathol; 169:431-437.
- *Lu, Q.L., Poulson, R., Wong, L. and Hanby, A. (1993):* bcl-2 expression in adult and embryonic non-haematopoietic tissues. J. Pathol., 169: 431- 437.
- *Lu,Q.L., Hanby,A.M. and Hajibagheri, M.A.N. (1994):* bcl-2 protein localizes to the chromosomes of mitotic nuclei and is correlated with the cell cycle in epithelia cell lines. J.Cell Sci., 107: 363-371.
- *Lucas W.E. (1981):* Estrogen-A case of Gynecologic cancer? Cancer 48-451.
- *Mabrouk, G.M., Helal, S.A., El-Lamie, K.I., Khalifa, A. (1996):* Quantitative measurement of c-erbB-2, p185 and mutant p53 expression in ovarian neoplasmas by enzyme immunoassay. Clin. Chem., 42: 981-982.
- *Mao, L. (1998):* Tumor Suppressor genes: Nat. Cancer Inst.; 90(6):412-414.
- *Markee, J.E. (1948):* Morphological basis of endometrial bleeding. Relation to regression to the onset of bleeding. Bull N. Y. Acad. Med., 24: 253- 270.
- *Marks, J.R., Davidoff, A.M., Kerns, B.J., et al (1991):* Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res., 51: 2979- 2784.
- *Martin, S.J. and Green, D.R. (1995):* protease activation during apoptosis: death a thousand cuts. Cell; 82:349-352.

-
- **Marx, J. (1993):** Cell death studies yield cancer clues. *Science*, 259: 760- 761.
 - **Mathew, F.K., Andrew, B.C. and Andrew, M.D. (1992):** Overexpression and mutation of p53 in endometrial cancer. *Cancer reserch.*, 52: 1627- 1637.
 - **Mc Donald P.C, Edman C.D, Hemsell D.L, porter J.C, Siiteri P.K (1978):** Effect of obesity on conversion of plasma Androstendione to Estrone in postmenopausal women with and without endometrial cancer. *Am. J. Obest., Gynecol*; 4:48-55.
 - **Mc Donnell T.J., (1994):** Significance of the t(14;18) translocation and bcl-2 gene deregulation in nonhodgkin's lymphoma. *Diag. Oncol.*, 4:18-21.
 - **Mc Donnell T.J., Korsmeyer S.J. (1991):** Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). *Nature*; 349:254-256.
 - **Meissner W.A, sommer S.C., and sherman G. (1957):** Endometrial hyperplasia, endometrial carcinoma and endometriosis produced experimentally by estrogen. *Cancer*; 10:500-509.
 - **Meyn, R.E. (1994):** Apoptosis: A fundemental mechanism in biology advances in leukaemia and lymphoma. Berlex laboratories, Richmond, California, USA., 4:3-6.
 - **Miturski, R., Semczuk, A., Tomaszewski, J. and Jakowicki, J. (1998):** bcl-2 protein expression in endometrial carcinoma: the lack of correlation with p53. *Cancer lett.*, 133: 63- 69.
-

-
- **Modrich, (1994):** Mismatch repair, genetic stability and cancer. Science; 266:1959.
 - **Monaghan P., Robertson D., Amos TAS., Mason DY., Greaves M.F. (1992):** Ultrastructural localization of bcl-2 protein. J Histochem Cytochem; 40:1819-1825.
 - **Monsier, J.F., Perrett, A.G., Vindimian, M., et al. (1996)):** An immuunohistochemical study of the simutaneous expression of bcl-2 and p53 oncoproteins in epithelial tumors of the colon and rectum. Arch. Pathol Lab. Med., 120: 654- 659.
 - **Mora, L.B., Diaz, J.I., Cantor, A.B. and Nicosia, S.V. (1999):** Differential diagnosis of endometrial hyperplsia and carcinoma by computerized image cytometry of cell proliferation, apoptosis and *bcl-2* expression. Ann. Clin. Lab. Sci., 29: 308- 315.
 - **Mueller, R. and Yourg, I. (1998):** The genetics of cancer In: Emery's Elements of Medical Genetics. Edited by R. Mueller and I. Young. 1oth ed. Churchill livingstone, Edinburgh, Chap. 13,P. 189-199.
 - **Nagamani. M, Doherty M.G, smith E.R., and chandrasekhar Y, (1992):** increased Bio active lutenizing hormore levels in post menopausal women with endometrial cancer. Am. J Obest Gyne cology; 167:1825-1830.
 - **Nakamura T., Nomura S., sakai T., and Nariya S. (1997):** Expression of bcl-2 oncoprotein in Gastrointestinal and uterine carcinomas and their premalignant lesions. Hum. Pathol; 28:309-315.

- **Nakamura, T., Sakai, T. and Nariya, S. (1995):** Cell death in colorectal polyps as evaluated by in situ 3'/tailing reaction and its relation with bcl-2 expression. *Pathol. Int*; 45:721-728.
- **Neil M.K., and lynne S.C. (1996):** Regulation of apoptosis by Bcl-2 and its related proteins: Immunochemical challenges and therapeutic implications. *J. Pathol*; 179:1-3.
- **Niemann, T.H., Trgovac, T.L., McGaughy, V.R. and Vaccarello, L. (1996):** bcl-2 expression in endometrial hyperplasia and carcinoma. *Gynecol. Oncol.*, 63: 318- 322.
- **Nischan P., and Ebeling K. (1991):** Endometrial cancer incidence and oral contraception. *Int. J. Epidemiol*; 20(3): 820-821.
- **Nunez, G., Hockenbery,D., McDonell,T.J. et al. (1991):** bcl-2 maintains B cell memory. *Nature*, 535: 71- 73.
- **Nures, P. (1994):** Ordering S phase and M phase in the cell cycle. *Cell*; 79:547-550.
- **Okamoto, A., Sameshima, Y., Yamada,Y., et al (1991):** Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. *Cancer Res.*, 51: 5632- 5636.
- **Oltvaiz.N., Milliman C.L., Korsmeyer S.J. (1993):** Bcl-2 heterodimerizes in vivo with a conserved homolog. Bax, that accelerates programmed cell death. *Cell*; 74: 609-619.
- **Oren, M. (1992):** p53 the ultimate tumor suppressor gene? *FASEB j.*, 6: 3169- 3176.

- ***Orman D.H (1990):*** The management of cancer of the uterine corpus, Clinical Gynecological Oncology. Second edition. Blackwell Scientific publication. Oxford: 115-139.
- ***Otsuki Y., Misaki O., Sugimoto O., et al., (1994):*** Cyclic Bcl-2 gene expression in human uterine endometrium during menstrual cycle. Cancer; 344:28-29.
- ***Quinn C.M. wright N.A. (1998):*** The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol; 160:93.
- ***Quinn MA, Andrson MC, coulter CAE, soutter W.P. (1997):*** Malignant disease of the uterus. In: Show RW, Soutter W.P., and Stanton S.L.: Gynecology, 2nd editien, london, Churchill livingstone, P. 587.
- ***Parker SL., Tong T., Bolden S., wingo P.A. (1996):*** Cancer statistics, Cancer J. Clin; 46:5-28.
- ***Partridge E.E. (1991):*** Endometrial cancer, changing concepts in therapy, Surgical Clinics of North America; 71(5):991-1004.
- ***Paul F., Kaminski, Edward S. podczaski (1997):*** Premalignant and malignant conditions of the uterus. In: Gynecologic pathology. Hernander E. and At Kinson B.F. edited by W.B. Saunders Company, Philadelphia: P.288.
- ***Pezzella, F., Tse, A.G., Cordell, J.L. et al (1990):*** Expression of the *bcl-2* oncogene protein is not specific for the 14,18 chromosomal translocation. Am. J. Pathol., 137: 225.

-
- **Pezzella, F., Turley, H. Kuzu, I., Tungekar, M.F., and Pierce, C.B. (1993):** *bcl-2* protein in non-small cell carcinoma. N. Engl. J. Med., 329: 690- 694.
 - **Piris, M.A., Pezzella, F., Martinez-Montero, J.C. et al (1994):** p53 and *bcl-2* expression in high-grade B-cell lymphomas: correlation with survival time. Br. J. Cancer, 69: 337- 341.
 - **Pirog, E. and Richart, R. (1999):** The cell cycle. OB/Gyn. Today; 3(3): 12-17.
 - **Pirog, E.C. and Czerwiniski, W. (1992):** Diagnostic and prognostic significance of the mitotic index in endometrial adenocarcinoma. Gynecol. Oncol., 46: 33- 40.
 - **Punnonen, R. Mattila, J., Kuoppala, T. (1993):** DNA ploidy, cell proliferation and steroid hormone receptors in endometrial hyperplasia and early adenocarcinoma. J. Cancer Res. Clin. Oncol., 119: 426- 429.
 - **Raff, M.C. (1990):** Social controls on cell survival and cell death. Nature, 356: 397- 400.
 - **Raskin, C.A. (1997):** Apoptosis and cutaneous biology. J. Am. Acad. Dermatol., 36(6): 885-890.
 - **Reed J.C, (1997):** Regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol; 34 (suppl5): 9-19.
 - **Reed J.C., Cuddy M., Halder. S., croce et al, (1990):** Bcl-2 mediated tumorigenicity of a human T.lymphoid cell line: Synergy with myc and inhibition by *bcl-2* antisense. Proc Natl Acad Sci USA; 87:3660-3664.

-
- **Reed J.C., Jurgensmeier J.M., and Matsuyama S. (1998):** Bcl-2 family proteins and mitochondria. *Biochim Biophys ACTA*; 1366:127-137.
 - **Reed, J.C. (1994):** *bcl-2* and the regulation of programmed cell death. *J.Cell Biol.*, 124: 1.
 - **Reinartz, J.J., George, E., Lindgren, B., et al (1994):** Expression of p53, transformonh growth factor alpha, epithelia growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survivals. *Hum. Pathol.*, 25: 1075- 1083.
 - **Ronnett, B.M., Burks, R.T., Cho, K.R. and Hedrick, L. (1995):** DCC expression in normal and neoplastic endometrial tissue. *Mod. Pathol.*, 8: 96A.
 - **Rotello, R.J., Hocker. M.B. and Gerschenson, L.E. (1989):** biochemical evidence for programmed cell death in rabbit uterine epithelium. *Am. J. Pathol.*, 134: 491- 495.
 - **Rowley J.D, Aster J.C, sklar J. (1998):** The clinical applications of new DNA diagnostic technology for the management of cancer patients: *JAMA*; 234:161.
 - **Sabourin, J.C., Martin, A., Baruch, J. et al (1994):** *bcl-2* expression in normal breast tissue during the menstrual cycle. *Int. J. Cancer*, 59: 1.
 - **Sachs, L. and Lotem, J. (1993):** Control of programmed cell death in normal and leukemic cells: new implications for therapy. *Blood*, 82: 15-21.
 - **Saegusa M., Kamata Y., Masako I., Okayasu I. (1996):** Bcl-2 expression is correlated with low apoptotic index and associated with
-

progesterone receptor immunoreactivity in endometrial carcinomas. *J. Pathol*; 180:275-282.

- **Sambrook, J., Fritsh, E.F. and Maniatis, T. (1989)** :Molecular cloningrd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory. 18: 42- 59.
- **Sato, S. (1993)**: Evaluation of the degree of biological behavior in endometrial hyperplasia and endometrial carcinoma. *Nippon Sanka Fujinka Gakkai Zasshi- Acta Obstetrica et Gynaecologica Japonica*, 45: 776- 788.
- **Selvakurmaran, M., Lin, H.K., Muyashita, T. et al (1994)**: Immediate early up-regulation of bac expression by p53 but not TGFB1: A paradigm for distinct apoptotic pathways. *Oncogen.*, 9: 1791.
- **Shaw R.W., Soutter W.P., and Stanton S.L. (1997)**: In: *Gynecology*, 2 nd edition, Churchill livingstone, London, P. 535-538.
- **Shaw, P., Bovey, R., Tardy, S., Sahi, B. and Costa, J. (1992)**: Induction of apoptosis by wild-type p53 in a human colon derived cell line. *Proc Natl. Acad. Sci. USA.*, 257: 242- 244.
- **Sheets, E.E. and Yeh, J. (1997)**: The role of apoptosis in gynecological malignancies. *Ann. Med.*, 29: 121-126.
- **Sherr C.J. (1994)**: G₁ phase progression: Cycling on cue. *Cell*; 79:551-555.
- **Sidway M.R., silverberg S.G, (1992)**: Endometrial carcinoma: Pathologic factors of therapeutic and prognostic significance. *Pathol. Annu*; 27:153-185.

- *Silverberg S.G (1984):* New aspects of endometrial carcinoma; Clinics in Obstet and Gynecology; Gynecological Pathology: Advances, Perspectives and Problems 11(1):189-268.
- *Silverberg S.G, Mullen. D, and faraci J.A (1980):* Endometrial carcinoma: Clinical-pathologic comparison of cases in postmenopausal women receiving and not receiving exogenous estrogens. Cancer; 45:3018-3056.
- *Skapek S.X, Rhee J, Spicer D.B, lassar A.B. (1996):* Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D₁ dependent Kinase. Science; 267:1022-1024.
- *Smith D.C., prentice R., Thompson D.J., and hermann W.L, (1975):* Association of exogenous estrogen and endometrial carcinoma. New England Journal of Medicine; 293:1164-1167.
- *Stephens, L.C., Ang, K.K., Schultheiss, T.E., Milas, L. and Meyn, R.E. (1991):* Apoptosis in irradiated murine tumors. Radiat. Res., 127: 308- 316.
- *Sutton G.P, Stehaman F.B, and look K.Y. (1990):* Endometrical cancer and uterine sarcomas. In: Principles and Practice of Clinical Gynecology, second Edition, Churchill livingstone, New York, 921-943.
- *Takano, Y.S., Harmon, B.V. and Kerr, J.F.R. (1991):* Apoptosis induced by mild hyperthermia in human and murine tumour cell lines: a study using electron microscopy and DNA gel electrophoresis. J Pathol., 163: 329- 336.

- **Tao, X.L., Tilly, K.I., Maravei, D.V., et al (1997):** Differential expression of members of the bcl-2 gene family in proliferative and secretory endometrium: Glandular epithelial cell apoptosis is associated with increased expression of bax. *J. Clin. Endocrinol. Metab.*, 82: 2738-2746.
- **Taskin, M., Lallas, T.A., Barber, H.R. and Shevchuk, M.M. (1997):** bcl-2 and p53 in endometrial adenocarcinoma. *Mod. Pathol.*, 10: 728-734.
- **Tenniswood M.P, Guenette R.S, Lakis J, Mooibroek M. (1992):** Active cell death in hormone dependent tissues. *Cancer Metastasis Rev*; 11:197.
- **Thompson C. (1996):** Apoptosis in the pathogenesis and treatment of disease. *Science*; 267:1456-1462.
- **Thompson J.D, and Rock J.A (1992):** In: Telande's Operative Gynecology. 7th edition, P. 1255-1262.
- **Thornton, J.G., Quirke, P. and Wells, M. (1989):** Flow cytometry of normal, hyperplastic and malignant human endometrium. *Am. J. Obstet. Gynecol.*, 161: 487.
- **Thrope, S.M., Lykesfeldt, A.D. and Vinterby, A. (1986):** Quantitative immunological detection of estrogen receptors in nuclear pellets from human breast cancer biopsies. *Cancer Res.* 46: 4249- 4266.
- **Tomei, L.D., Kanter, P. and Wenner, C.E. (1988):** Inhibition of radiation-induced apoptosis in vitro by tumor promoters. *Biochem. Biophys. Res. Commun.*, 155: 221- 224.

- **Torn, V.A., Krajewski, S., Klein-Parker, H., et al (1995):** Immunohistochemical analysis of *bcl-2* protein regulation in cutaneous melanoma. *Am.J. Pathol.*, 146: 643.
- **Tsujimoto, Y., Cossman, J., Jaffe, E. and Corce, C. (1985):** Involvement of the *bcl-2* gene in human follicular lymphoma. *Science*, 228: 1440.
- **Tsujimoto Y., Finger I.R., Yunis J., et al. (1984):** Cloning of the chromosome breakpoint of neoplastic B cells with the T(14;18) chromosome translocation. *Science*; 226:1097-1099.
- **Tsujimoto, Y. (1989):** Overexpression of the human *bcl-2* gene product results in growth enhancement of Epstein-Barr virus-immortalized B cells. *Proc. Natl. Acad. Sci. USA*, 86: 1958- 1962.
- **Ulbrich, A. and Schlessinger, J. (1990):** Signal transduction by receptors with tyrosine kinase activity. *Cell*; 61:203-212.
- **Vaux D.L. (1993):** Toward an understanding of the molecular mechanisms of physiological cell death. *Proc. Natl. Acad. Sci. USA*; 90:786-9.
- **Villard L, and Murphy M:** Endometrial cancer trends in England Wales: A possible protective effect of oral contraception *Int. J. Epidemiol*; 19: 255-258.
- **Vogelstein B, Kinzler KW. (1998):** The multistep nature of cancer. *Trends Genet*; 9: 138.

- **Webb, A., Cunningham, D., Cotter, F., Clarke, P.A., Stefano, F. di., Ross, P. and Dziewanowska, Z. (1997):** *bcl-2* antisense therapy in patients with non-Hodgkin lymphoma. *Lancet*, 349: 1137- 1341.
- **Weinder N, Carroll P. R, Flax J, Blumenfeld W, Folkman J. (1993):** Tumor angiogenesis correlates with metastases in invasive prostate carcinoma. *Am. J. Pathol*; 143: 401.
- **Wheaton, S., Netser, J., Guinee, D., Rahn, M. and Perkins, S. (1998):** *bcl-2* and Bax protein expression in indolent versus aggressive B-cell non-Hodgkin's lymphomas. *Hum. Pathol.*, 29: 820- 825.
- **White, E. (1996):** Life, death, and the pursuit of apoptosis. *Genes Dev.*, 10: 1-15.
- **White, L.N. (1993):** An overview of screening and early detection of gynecologic malignancies. *Cancer*, 71: 1400.
- **Widra EA, Dunton CJ, McHugh M, Palazzo JP (1995):** Endometrial hyperplasia and the risk of carcinoma. *International Journal of Gynecological Cancer*; 5: 233-235.
- **Williams, G. T. and Smith, C. A. (1995):** Molecular regulation of apoptosis: Genetic controls on cell death. *Cell*; 74: 777-781.
- **Williams, G.T. (1991):** Programmed cell death: apoptosis and oncogenesis. *Cell*, 65: 1097- 1098.
- **Williams, J. H., Carlos, A. P., and Robert, C. Y, (1997):** In *Principles and Practice of Gynecologic Oncology* 2nd ed., lippicott-Raven Publishers, New York; P. 605-607.
- **Williams, P. L. and Warwick, R. (1980):** Cytology. In: Gray's anatomy. 36th edn. Churchill Livingstone, London, P. 23.

- *Wyllie, A.H. (1987):* Apoptosis: cell death under homeostatic control. Arch. Toxicol. Suppl., 11: 3- 10.
- *Wyllie, A.H. (1992):* Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: An over view. Cancer Metast. Rev.; 11: 95-103.
- *Wynder, E.L., Escher, G.C. and Mantell, N. (1966):* An epidemiological investigation of endometrial cancer. Cancer, 19: 489.
- *Yamauchi, N., SAKAMOTO, a. and Uozaki, H. (1996):* Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression to sex steroid receptor and proliferative activity. Int. J. Gynecol. Pathol., 15: 202- 208.
- *Yang E., Zha J., Jockel J, et al. (1995):* Bad, a heterodimeric partner for Bcl-xL and Bcl-2 displaces Bax and promotes cell death, Cell; 80: 285-291.
- *Zaino, R. J. (1992):* Endometrial carcinoma: the need to pursue a new pathology. *Gynecol. Oncol.*, 45: 233.